TY - JOUR
T1 - Retroperitoneal lymph node recurrence of epithelial ovarian cancer
T2 - Prognostic factors and treatment outcome
AU - Levy, T.
AU - Migdan, Z.
AU - Aleohin, N.
AU - Ben-Shem, E.
AU - Peled, O.
AU - Tal, O.
AU - Elyashiv, O.
N1 - Publisher Copyright:
© 2020
PY - 2020/5
Y1 - 2020/5
N2 - Objective: To evaluate the treatment outcome and survival of patients with epithelial ovarian cancer recurrence isolated to the retroperitoneal lymph nodes compared to intraperitoneal spread. Methods: A retrospective cohort study including women with recurrence of epithelial ovarian, cancer, who were treated at a single medical center, between 2000 and 2015. Patients were classified into three groups according to the site of recurrence: intraperitoneal only, retroperitoneal lymph nodes only, and both. Response to treatment was assessed by the RECIST criteria. Results: Out of 135 patients in our cohort, 66 were diagnosed with intraperitoneal recurrence, 30 with retroperitoneal lymph node recurrence and 39 with combined site recurrence. The clinical, pathological and surgical characteristics were similar among all groups, besides CA-125 which was significantly lower in the retroperitoneal recurrence group at diagnosis, end of treatment and recurrence. The median follow-up period was 45.8 months. Overall survival (OS) and post relapse survival (PRS) were significantly higher in the retroperitoneal recurrence group vs. the intraperitoneal and combined site recurrence groups. (OS – 93.07, 47.9 and 41.7 months, respectively, p < .001, PRS – 68.57, 29.67 and 19.7 months, respectively, p < .001). On cox's regression analysis, retroperitoneal recurrence was found to be an independent prognostic factor for survival. Conclusions: The site of recurrence has significant prognostic value regarding PRS and OS. Patients with recurrence limited to the retroperitoneal lymph nodes have a favourable prognosis with median survival longer than 5 years.
AB - Objective: To evaluate the treatment outcome and survival of patients with epithelial ovarian cancer recurrence isolated to the retroperitoneal lymph nodes compared to intraperitoneal spread. Methods: A retrospective cohort study including women with recurrence of epithelial ovarian, cancer, who were treated at a single medical center, between 2000 and 2015. Patients were classified into three groups according to the site of recurrence: intraperitoneal only, retroperitoneal lymph nodes only, and both. Response to treatment was assessed by the RECIST criteria. Results: Out of 135 patients in our cohort, 66 were diagnosed with intraperitoneal recurrence, 30 with retroperitoneal lymph node recurrence and 39 with combined site recurrence. The clinical, pathological and surgical characteristics were similar among all groups, besides CA-125 which was significantly lower in the retroperitoneal recurrence group at diagnosis, end of treatment and recurrence. The median follow-up period was 45.8 months. Overall survival (OS) and post relapse survival (PRS) were significantly higher in the retroperitoneal recurrence group vs. the intraperitoneal and combined site recurrence groups. (OS – 93.07, 47.9 and 41.7 months, respectively, p < .001, PRS – 68.57, 29.67 and 19.7 months, respectively, p < .001). On cox's regression analysis, retroperitoneal recurrence was found to be an independent prognostic factor for survival. Conclusions: The site of recurrence has significant prognostic value regarding PRS and OS. Patients with recurrence limited to the retroperitoneal lymph nodes have a favourable prognosis with median survival longer than 5 years.
KW - Epithelial ovarian cancer
KW - Lymph node recurrence
KW - Peritoneal recurrence
KW - Post relapse survival
KW - Response to chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85081269103&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2020.02.022
DO - 10.1016/j.ygyno.2020.02.022
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32151375
AN - SCOPUS:85081269103
SN - 0090-8258
VL - 157
SP - 392
EP - 397
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -
